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The enzyme hydroxymethylbilane synthase (HMBS; EC 4.3.1.8), also known as
porphobilinogen deaminase, catalyses the stepwise addition of four molecules of
porphobilinogen to form the linear tetrapyrrole 1-hydroxymethylbilane. Thirty
years of crystal structures are surveyed in this topical review. These crystal
structures aim at the elucidation of the structural basis of the complex reaction
mechanism involving the formation of tetrapyrrole from individual porpho-
bilinogen units. The consistency between the various structures is assessed. This
includes an evaluation of the precision of each molecular model and what was
not modelled. A survey is also made of the crystallization conditions used in the
context of the operational pH of the enzyme. The combination of 3D structural
techniques, seeking accuracy, has also been a feature of this research effort.
Thus, SAXS, NMR and computational molecular dynamics have also been
applied. The general framework is also a considerable chemistry research effort
to understand the function of the enzyme and its medical pathologies in acute
intermittent porphyria (AIP). Mutational studies and their impact on the
catalytic reaction provide insight into the basis of AIP and are also invaluable
for guiding the understanding of the crystal structure results. Future directions
for research on HMBS are described, including the need to determine the
protonation states of key amino-acid residues identified as being catalytically
important. The question remains – what is the molecular engine for this complex
reaction? Thermal fluctuations are the only suggestion thus far.
1. Introduction
The course of the reaction catalysed by hydroxymethylbilane
synthase (HMBS) is depicted in Fig. 1 as well as its overall
position in the pathway to uroporphyrinogen III (Hädener et
al., 1999). Note the ammonia molecules released in each step.
The crystal structure with PDB code 1ah5 (Hädener et al.,
1999) is depicted in Fig. 2.
2. Commentary on the role of the PDB data files in
structural and functional studies of HMBS
The details of each deposition are provided in Table 1. A
synopsis of the role of each crystal structure is now provided.
The HMBS structures studied are from multiple organisms;
these are listed in Table 1. It is made clear to which organism
the amino-acid numbering of the highlighted residues below
refers.
PDB entry 1pda. This is the opening, pioneering, crystal
structure. It was of the inactive form of the enzyme. Louie et
al. (1992) suggested that the enzyme mechanism has two
options: the sliding of the catalytic residue Asp84 (Escherichia
ISSN 2053-230X
coli numbering) or the movement of the cofactor past Asp84,
in which the relative motion of the individual domains is also
likely to be involved.
PDB entry 1ah5. This is the active form of the enzyme and
was solved by selenomethionine MAD phasing using Station
9.5 at the SRS in the UK (Hädener et al., 1993, 1999). This
study also gave early experience of the ESRF BM14 beamline
and the ESRF image-intensifier detector (Cassetta et al.,
1999). In Hädener et al. (1999), the SRS and ESRF MAD data
and results are also compared.
PDB entry 1ypn. This was the first experimental demon-
stration of the active-site location. It corresponds to the 2 h
time point after reaction initiation by diffusion of porpho-
bilinogen (PBG) into the crystal using a flow cell monitored by
time-resolved diffraction on ID09 at ESRF. The experiment
was based on the K59Q HMBS mutant, experiments using
which had shown a buildup of the enzyme–substrate inter-
mediate ES2 (Niemann et al., 1994). Extended electron density
was established after 2 h in a geometric series of measured
time-point data sets from 1 min to 12 h. PBG fits the 2 h
extended electron density (2Fo  Fc); this is likely to be the
first reaction site (ES1) as it is proximal to Asp84. The other
end of the elongated density extended towards the side chain
of Arg149, which is also an important residue. The maximum
peak height was around 3.8 and the length of the peak was
around 8 Å. The enzyme–substrate intermediate complexes
require a covalent bond between the C2 ring of the cofactor
and ring A of the polypyrrolic chain. However, the 2 h elon-
gated density peak is not connected to the C2 ring of the
cofactor; this point is discussed further below.
PDB entry 2ypn. This was the time-zero data set that
accompanied PDB entry 1ypn from the experiment on ID09 at
ESRF.
PDB entry 1gtk. This crystal structure determination was
from diffraction data that were measured at 100 K and was
compared with PDB entry 1ah5, the room-temperature crystal
structure. However, the mobile loop consisting of residues
45–57, which sits close to the active site of HMBS, was not
stabilized in PDB entry 1gtk. This loop was defined structur-
ally in PDB entry 4htg, the Arabidopsis enzyme (Roberts et al.,
2013), as well as being offered as a predicted structure by
AlphaFold DB (Jumper et al., 2021).
PDB entries 3ecr, 3eq1, 4htg, 4mlq and 4mlv are crystal
structures of HMBS from other species and organisms. PDB
entries 3ecr and 3eq1 are of human HMBS and are especially
interesting because the mutations responsible for the genetic-
based disease acute intermittent porphyria could be directly
visualized in these human HMBS crystal structures. PDB entry
5h6o is listed as ‘to be published’ and the PDB deposition is
entitled Porphobilinogen deaminase from Vibrio cholerae.
PDB entries 5ov4, 5ov5 and 5ov6 are crystal structures that
each involve a mutant of the catalytic aspartic acid (Asp82 in
Bacillus megaterium numbering). Guo et al. (2017) reported
that ‘the only mutant, D82E, which has the whole cofactor
bound in a well ordered manner is catalytically active, while
the other two (D82A and D82N) are not’.
Since 2018, several groups have reported studies of ES2
intermediate structures. These structures are as follows.
PDB entry 5m6r (Pluta et al., 2018) is a structure entitled
Human porphobilinogen deaminase in complex with reaction
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Figure 1
The biosynthesis of uroporphyrinogen III from 5-aminolevulinic acid. The enzymes involved are (a) 5-aminolaevulinic acid dehydratase, (b)
hydroxymethylbilane synthase (HMBS) and (c) uroporphyrinogen III synthase. A = CH2COO
; P = CH2CH2COO
. Reproduced from Hädener et al.
(1999).
intermediate ES2. Note the 3.5 Å change in the c unit-cell
parameter compared with PDB entry 5m7f, the holo enzyme.
PDB entry 7aak (Bustad et al., 2021) is a structure entitled
Human porphobilinogen deaminase R173W mutant crystal-
lized in the ES2 intermediate state. The maximum differences in
unit-cell parameters compared with PDB entry 7aaj, the holo
enzyme, are the values of b and c, which differ by 1.5 Å, i.e. the
ES2 intermediate was captured with only a small unit-cell
change.
PDB entry 7cdo (Sato et al., 2021) is a structure entitled
Crystal structure of the 2-iodoporphobilinogen-bound ES2
intermediate form of human hydroxymethylbilane synthase.
The crystals used by Sato and coworkers are shown in their
Supplementary Fig. S3. 2-Iodoporphobilinogen (2-I-PBG) is
described by Sato et al. (2021) as a noncompetitive inhibitor.
From the same group of studies is PDB entry 7ccy entitled
Crystal structure of the 2-iodoporphobilinogen-bound holo
form of human hydroxymethylbilane synthase. Note the 7.4 Å
difference in the a unit-cell parameter compared with PDB
entry 7cd0. PDB entry 7ccz is entitled Crystal structure of the
ES2 intermediate form of human hydroxymethylbilane synthase
and PDB entry 7ccx is entitled Crystal structure of the holo
form of human hydroxymethylbilane synthase. Note that the a
unit-cell parameter of PDB entry 7ccx differs by 4 Å
compared with that of PDB entry 7ccy and by 11 Å compared
with those of PDB entries 7ccz and 7cdo. In effect there are
two unit-cell clusters here, albeit broadly similar. The use of
2-I-PBG by Sato et al. (2021) is interesting. They showed that
it inhibited the HMBS reaction in a noncompetitive manner.
Sato and coworkers reported that ‘this contrasted with
reported competitive and mixed-type inhibitors, such as
2-bromo-PBG and 6-methyl-PBG, respectively, which form
covalent bonds with the cofactor and oligopyrrole chain, while
2-I-PBG does not form such’. They also reported that ‘The
overall structure of the 2-I-PBG-bound holo-HMBS was
found to be similar to that of the inhibitor-free holo-HMBS’.
Table 2 of Sato et al. (2021) provides comprehensive details of
the interactions between pyrroles and the protein moiety in
HMBS (in their four crystal structures). Fig. 8 of Sato et al.
(2021) shows a predicted ES1 based on their crystal structure
of human HMBS complexed with 2-I-PBG. As a historical
note, bromoporphobilinogen was important in the study of the
enzyme, as experiments by Warren & Jordan (1988) using
bromoporphobilinogen provided conclusive evidence for the
direct covalent interaction of the substrate with the dipyrro-
methane (DPM) cofactor.
In mid-2021 the AlphaFold Protein Structure Database
(AlphaFold DB; Jumper et al., 2021) was announced by
DeepMind and the EMBL–EBI (the European Bioinfor-
matics Institute, part of the European Molecular Biology
Laboratory; https://alphafold.ebi.ac.uk/). This database spans
20 species and includes, for example, the predicted 3D struc-
ture of E. coli HMBS (Jumper et al., 2021; Tunyasuvunakool et
al., 2021). This includes a predicted structure for loop 45–57,
which has often been missing in the experimental structures.
3. Discussion
There are two principal themes in structural studies of this
enzyme. The first is to unravel the details of the structural
rearrangements during catalysis involving tetrapyrrole poly-
merization and release of a product (see Fig. 1) of precisely
four units. The second theme is to relate the key amino-acid
changes in the HMBS structure to the medical pathology acute
intermittent porphyria (AIP). These two themes interrelate as
the latter can be harnessed to inform the former, i.e. so as to
trap intermediate states. Song et al. (2009) mapped a number
of mutations that had been documented in the porphobilino-
gen deaminase (PBGD) gene of patients suffering from AIP
onto their crystal structure of human PBGD (PDB entry 3ecr).
The method of mutagenesis to fully trap an enzyme inter-
mediate state such as ES2 has the danger that the enzyme is
effectively blocked and cannot move towards extending to the
next step and on towards release of the product. The danger
then is that the crystal structures are artefactual or, if not
topical reviews
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Figure 2
(a) The crystal structure of the active form of the E. coli HMBS enzyme in
ribbon format (PDB entry 1ah5); the cofactor is in the middle of the
picture. (b) An enlargement of the dipyrromethane cofactor; the right-
hand cofactor ring (referred to in the text as C1) is covalently attached to
the labelled Cys242 (Cys261 in the human enzyme). The Asp side chain
(Asp84 in E. coli HMBS and Asp99 in human HMBS) is visible just below
the cofactor towards its left-hand side. This figure was produced by
CCP4mg (McNicholas et al., 2011).
topical reviews





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exactly that, then at least not natural. A mutant such as K59Q
(Niemann et al., 1994) does not fully stop the enzyme at this
second stage; rather, it slows the process down, which I think is
a better approach to the natural state of the enzyme. In this
case the X-ray diffraction experiment has to be sufficiently
quick in its measurements to capture this accumulating
population (Helliwell et al., 1998).
An alternative to time-resolved diffraction is to freeze-trap
at the key stage of a sufficient accumulated intermediate, using
the time sequence established by the flow-cell method.
Alternatively, since the pre-formed crystal itself could restrict
movements due to crystal packing, the consistency of the
intermediate trapped structures could be explored in experi-
ments repeated on different crystal forms.
Pluta et al. (2018) elegantly combine techniques to obtain
results in solution using NMR for structural details and solu-
tion scattering for overall HMBS shape monitoring. These
results ‘suggest a reaction mechanism with localized segmental
dynamics, ruling out the domain-reorienting mechanism’.
Their crystallization was directly of the ES2 enzyme substrate
intermediate eluted from a chromatography column (see Fig. 1
of Pluta et al., 2018). They explain that
These results (crystal structures PDB 5m7f and 5m6r based on
3ecr of Song et al., 2009), combined with the SAXS and NMR
experiments, allow us to propose a mechanism for the reaction
progression that requires less structural rearrangements than
previously suggested [by Louie et al. (1992)]: the enzyme slides a
flexible loop (R255-V263) over the growing-product active site
cavity . . . The large number of AIP-causing mutations occurring
in this loop confirms the key relevance of this structural element
not only for the reaction but also in disease.
For comparison purposes with E. coli, the sequence of this key
loop Arg255–Val263 in the human enzyme would be Asn235–
Gln243, encompassing Cys242, which is covalently attached to
the cofactor ring C1 (see PDB entries 1ah5, 1ypn and 2ypn). It
is this covalently linked cysteine (Cys261) that pulls the
cofactor past the catalytic Asp99 (Asp84 in E. coli). Supple-
mentary Figs. S4 and S5 of Pluta et al. (2018) show the crystals
of Eholo and ES2, which are colourless.
4. Consistencies and inconsistencies in the crystal
structures
In addressing the goal of elucidating the mechanism of the
enzyme, we can ask: what are the consistencies and incon-
sistencies in the crystal structures thus far? Here we are mainly
addressing the group of crystal structures with PDB codes
1ypn, 5m6r, 7aaj, 7aak, 7cdo and 7ccz.
4.1. Consistency of the active-site structures of the ES2
intermediate
Firstly, Fig. 3 shows the best least-squares-calculated
overlay of molecule A of the cofactor plus ES2 in PDB entries
5m6r and 7aak. These structures, which are both of human
HMBS, are remarkably consistent considering that they were
obtained by two different groups in two different space groups
topical reviews


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and one is an Arg173Trp mutant form of the enzyme. This
mutation was chosen as it prevents the formation of ES3 [see
Fig. 2(d) of Bustad et al. (2021), which is a mass spectrum
showing only ES2]. These two crystal structures agree that the
new pyrrole rings S1 and S2 occupy the original positions of
the C1 and C2 rings of the DPM cofactor in the HMBS
enzyme structure.
An important observation of Bustad et al. (2021) is in the
caption to their Supplementary Fig. S5, where they state that
‘Upon the movement of cofactor-binding loop from Eholo to
ES2 only small change in Val263 can be detected’. This is
shown in Fig. 4, which emphasizes that it is the motion of
Cys261 itself that is largely responsible for pulling the cofactor
to make room for the addition of two PBG molecules to form
ES2.
Fig. 5 documents similar agreement for the cofactor plus
ES2 for PDB entries 5m6r and 7cd0. Similar agreement for ES2
is shown by PDB entry 7ccz.
4.2. Time-resolved diffraction experiment on the Lys59Gln
mutant of HMBS to accumulate ES2
PDB entry 1ypn from the time-resolved study showed the
growth of an extended electron density from the region of
Asp84 and cofactor ring C2. Like those used for PDB entry
1ah5, the crystals used for PDB entry 2ypn were colourless
before the flow of PBG over the crystals, with the cofactor in
the active state. In the case of PDB entry 1ypn, after 2 h of
PBG flow the crystals became pink/red (see Section 4.2.4 of
Helliwell et al., 1998). To achieve the full red colour at 12 h
requires release of the product and cyclization of the tetra-
pyrrole. After the PBG supply had been turned off at the 2 h
time point, a crystal structure was determined at 12 h. The
extended electron density that grew in the active site by 2 h
had disappeared, whilst the crystal at 12 h was red. How do we
reconcile these observations with the agreed model (Figs. 3, 5
and 6) of the cysteine bond (Cys261 in human HMBS,
corresponding to Cys242 in E. coli HMBS) to cofactor ring C1
topical reviews
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Figure 3
Best least-squares-calculated overlay of the cofactor plus ES2 for human
HMBS, PDB entries 5m6r and human 7aak, in molecule A. Molecule B
also shows a similarly good agreement between PDB entries 5m6r and
7aak. (a) was made with Coot (Emsley et al., 2010), and (b) and (c) were
made with CCP4mg (McNicholas et al., 2011). All three show very similar
orientations and show complementary information. Cys261 is covalently
linked to the first ring of the cofactor. The least-squares-calculated
overlay of PDB entries 5m6r and 7aak used the five amino acids centred
on Asp99.
Figure 4
The motion of (human) Cys261 itself is largely responsible for pulling the
cofactor to make room for the addition of two PBG molecules to form
ES2 (Bustad et al., 2021). The movement of Cys261 (PDB entries 7aaj and
7aak, molecules A) is 4.4 Å and that of Val263 is 0.8 Å. The movement of
Asp99 is 0.5 Å. (a) shows the alpha carbons and the cofactors and ES2; (b)
shows an identical view with all atoms.
pulling the growing pyrrole chain so that S1 and S2 occupy the
sites originally occupied by C1 and C2? One option referred to
in Helliwell et al. (1998) was that the red colour arises from the
enzyme molecules on the crystal surface only and therefore
the extended electron density that grew in the active site was
only the arrival of PBG in the active site. Indeed, there was no
bond to the C2 ring, which would support this; i.e. it was a pre-
reactive species. The results shown in Figs. 3, 5 and 6 suggest a
new possibility: that the reaction in the crystal from which
PDB entry 1ypn was obtained had gone to EP, the cofactor
had returned to its starting position, and the bond between S4
and the cofactor C2 ring would also have been broken. This is
only viable if Cys242 and the nearby loop residues 243
onwards were able to move unrestrictedly, i.e. if there was a
solvent channel directly above the loop. Otherwise, the loop
would fight against the crystal packing and the crystal would
most likely have broken up. Fig. 6 shows that there is a solvent
channel directly above this loop. Against this second
hypothesis is that we did not directly see sliding of the DPM
cofactor or of the Cys242 associated with it (at most 0.1 Å at
8 min; see Fig. 4 of Helliwell et al., 1998).
To return to the visual observations made in Section 4.2.4 of
Helliwell et al. (1998): ‘In separate experiments involving the
soaking of a wild-type HMBS crystal in a pot of solution the
pink/red colour developed in similar fashion to the flow cell
experiments.’ Furthermore,
After ca. 24 h the crystal showed distinct cracks and the
surrounding solution also became gradually pink within 13–24 h,
but markedly more slowly than the crystal (results of A.
Hädener). These observations are consistent with formation of a
cyclized oxidized product in the crystal, which may or may not
be released from the active site. It cannot be ruled out, however,
that non-enzymatic formation of tetrapyrrole in solution and
subsequent cyclization and oxidation processes are followed by
the absorption of the oxidized material by the crystal, thus
concentrating it like a red dye.
It is also interesting that Azim et al. (2014) contains an
extensive discussion of their cofactor states and colourations
(pink as well as yellow). They noted an ‘intriguing pink
colouration of the freshly purified protein which gradually
changes to yellow over a 2–3-week period.’
4.3. What is the role of the loop 61–76 (human HMBS
numbering)?
PDB entries 4htg, 5m6r and 7aak are exceptions in that they
show the ordering of this loop. Actually, however, PDB entries
5m6r and 7aak, which each have two HMBS molecules in their
asymmetric units, have disordered loops in one of these two
HMBS molecules. Yet both PDB entries 5m6r and 7aak have
their two HMBS molecules with fully formed C1+C2+S1+S2
in their ES2 crystal structures. This suggests that the role of
this loop is incidental to the catalytic sequence of events, at
least up to ES2. However, Sato et al. (2021) report that ‘flex-
ibility of this loop in the proximity of the active site appears to
be involved in the binding of 2-I-PBG and the substrate,
although no direct interactions between the loop (residues 58–
69) and 2-I-PBG were observed’. This last sentence seems to
be a little self-contradictory.
4.4. What can be said about the ES2 to ES3 step?
As the experimental design in Bustad et al. (2021) involved
the R173W mutant and they showed conclusively that ES3 was
topical reviews
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Figure 5
Best least-squares-calculated overlay of the cofactor plus ES2 for human
HMBS, PDB entries 5m6r and human 7cd0, in molecule A. Molecule B
shows very similar agreement. Cys261 is at the lower middle and thereby
also identifies the first ring of the cofactor. Note that the iodinated PBG
inhibitor is in molecule B. (a) was made with Coot (Emsley et al., 2010)
and (b) was made with CCP4mg (McNicholas et al., 2011). Both show
very similar orientations and show complementary information. Cys261 is
covalently linked to the first ring of the cofactor. The least-squares-
calculated overlay of PDB entries 5m6r and 7cd0 used the five amino
acids centred on Asp99.
Figure 6
Crystal-packing diagram for E. coli (PDB entry 1ypn) showing the
solvent channel directly above the 242–255 polypeptide loop of HMBS.
Note that the lattice neighbour of Gly255 is Gly33 and residue 32 is a
proline, i.e. it is unlikely to interfere with loop movement.
not produced, then it is compelling to agree with Bustad et al.
(2021) that ‘the substrate elongation from ES2 to ES3 is
crucially dependent on Arg173’. Secondly, since Pluta et al.
(2018) actually crystallized ES2 for the wild-type enzyme and
Fig. 3 shows the agreement between the two approaches, this
lends further support to the crucial role of Arg173.
Sato et al. (2021) came the closest to a crystal structure of
ES3; they reported that they ‘attempted crystallization and
structure analysis of ES3 intermediate of HMBS, and
successfully obtained its crystals. However, structural analysis
of the ES3 intermediate has not yet been successful due to its
instability.’ However, they make the very plausible conclusion
from their several crystal structures that ‘Since 2-I-PBG is
present at the same site in both structures (holo hHMBS and
ES2), it is considered that each of the four substrate molecules
binds to a single substrate-binding site in HMBS and is
condensed consecutively on the DPM cofactor in four
successive reactions.’ This assertion then provides a definite
suggestion regarding ES3 and ES4 formation. Also, it should
be considered that the step from ES2 to ES3 requires further
rearrangement, which cannot happen in the crystal state.
Therefore, ES3, stabilized somehow, may need to be formed
before crystallization.
4.5. What can be said about how the product is released?
Bung et al. (2014, 2018, 2019) undertook molecular-
dynamics (MD) studies. Fig. 7 from Bung et al. (2018) and the
associated text describe three possible routes for the formed
product to exit the enzyme. Specifically, they state that ‘R167
acts as a gatekeeper for the HMB exit’. In his PhD thesis, Nieh
offered a similar assertion based on the 2 h time-resolved
experiment (Nieh, 1997):
The elongated peak passes the critical residues Arg149, which is
important in forming ES2, and approaches Arg155, which is
important in the ES4 to EP step, and then projects out into the
solvent channel. Residues Arg149 and Arg155 in E. coli are
equivalent to residues 167 and 173 in the human HMBS enzyme
and mutation of these two residues can cause acute intermittent
porphyria. The modelling of EP is shown in Fig. 6.13 [reproduced
here as Fig. 7] with the final omit map overlaid. Note that only
ring A gives a reasonably detailed fit.
4.6. Consistency given by combining different methods
Bustad et al. (2021) elegantly show how high-resolution
mass spectrometry allows direct analysis of the intermediates
in order to directly plan the X-ray crystal structures. A
weakness of an X-ray crystal structure is that where there is
disorder, such as a mobile loop or a floppy tripyrrole or
tetrapyrrole, there will be broken up or missing electron
density. However, if the mass is directly measured then this
datum assumes a special importance. This approach of
measuring the mass was also performed by Sato et al. (2021).
The role of SAXS where there might be large-scale inter-
domain movements, as originally proposed for HMBS by
Louie et al. (1992), can be definitive and shows what is
happening in solution. However, if the mechanism has been
shown to be the localized movement of Cys261, without inter-
domain movements, then SAXS will be insensitive to such
localized changes.
The role of monitoring the colour, from colourless to pink
to full red, is illustrated well in the efforts to unravel the
mechanism of HMBS. The colour changes have been
emphasized several times above.
X-ray crystal structures at these diffraction resolutions
cannot show the H atoms of ionizable groups, or even at
ultrahigh resolution if the side chains are a little mobile. [Non-
ionizable groups can have their H atoms placed in calculated
positions with confidence.] Since molecular-dynamics
topical reviews
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Figure 7
Stereoview of the modelling of the Michaelis complex EP (red) overlaid with the 2 h time point (Fo Fc) electron-density omit map contoured at 2.00.
From Nieh (1997). The acetate and propionate side chains of the second, third and fourth pyrroles could not be placed due to insufficient detail in the
density map.
simulations propose a mechanism relying on the protonation
of incoming PBG molecules by Arg26, and electrophilic
addition and deprotonation in concert with Asp99 (Bung et al.,
2018, 2019), then experiments seeking to place these H atoms,
and as a function of time, are the most challenging of all.
Neutron crystallography of suitably trapped intermediate
states through wet chemistry or freeze-trapping has not yet
been applied. These experiments would require larger crystals
to be grown than hitherto. It is also worth noting that the pH
optimum of the E. coli HMBS enzyme is 7.4–8.0, yet the best
crystallization conditions thus far were at pH 5.3. As Hädener
et al. (1999) remark
The pH optimum for HMBS from E. coli is between 7.4 and 8.0,
and the isoelectric point is 4.5. Within the optimal pH interval
and for the overall reaction, the Michaelis constant is between 5
and 20 mM, and the turnover constant is of the order of 0.1 s1
with respect to the formation of HMB.
Functionally relevant protonation states will require crystals
that are grown under functionally appropriate conditions.
To summarize, the human HMBS crystallization conditions,
and in one case the solution for SAXS measurements, were as
follows.
Song et al. (2009) state in PDB entry 3ecr that the pH of
their human HMBS crystallization was 8.0 (this was not stated
in their paper).
The crystallization conditions used by Pluta et al. (2018) for
human HMBS were between pH 6.5 and 7.2, and their SAXS
solution was at pH 8.5.
The crystallization conditions used by Bustad et al. (2021)
for human HMBS were at pH 5.1.
The crystallization conditions used by Sato et al. (2021) for
human HMBS were at pH 8.3.
In addition to the extensive MD simulations of Bung et al.
(2019) described above, MD calculations of the ES2 inter-
mediate were also undertaken by Sato et al. (2021). These
suggested that thermal fluctuation of the lid (residues 58–75,
human numbering) and cofactor-binding loops causes the
substrate recruitment and oligopyrrole chain shift needed for
consecutive condensation. This suggestion relates to the
observation by Bustad et al. (2021) that Cys261 is the locus of
the movement of the cofactor during catalysis, but what is the
‘engine’ or energy to drive this movement? Perhaps Sato et al.
(2021) have the answer, namely thermal fluctuation (of the lid
and cofactor-binding loops). However, thermal fluctuations
are random displacements rather than being purposeful in a
particular direction. The MD simulations performed by Sato et
al. (2021) required the protonation states of Glu223 and
His160; at these diffraction resolutions these needed to be
predicted, which was performed using the H++ server (http://
biophysics.cs.vt.edu). An evaluation of the predictive accuracy
of several prediction servers has been undertaken by Fisher et
al. (2009), who concluded that predicting histidine protonation
was especially difficult. Sato et al. (2021) provide three movie
files; the first two show the jittery nature of a wide suite of
atomic motions and the third movie, of the ES2 in HMBS in
skeletal format, very clearly shows the simulated dynamic role
of loops.
5. Future directions
Experimental capabilities for time-resolved diffraction have
expanded considerably. The new extremely bright synchrotron-
radiation sources such as those at MAX IV and ESRF will
allow smaller protein crystal sizes. In the experiments of
Helliwell et al. (1998) the E. coli HMBS crystals were typically
0.5  0.5  0.05 mm in size. The human HMBS crystals used
by Sato et al. (2021) were 0.2  0.2  0.02 mm for the
inhibitor-free holo form and 0.1  0.1  0.01 mm for the
inhibitor-free ES2 intermediate. The diffusion time of PBG
into the crystal for smaller crystals would be speeded up
accordingly. These would also likely lead to better quality (less
mosaic) freeze-trapping of crystals in intermediate states. This
said, there is a growing awareness of examples of cryo-
artefacts which must be guarded against, such as incorrectly
placed side chains and their bound waters (see, for example,
Halle, 2004).
The availability of high-quality protein fold and structure
predictions across multiple species from AlphaFold DB
(Jumper et al., 2021; Tunyasuvunakool et al., 2021) will allow
further insights into the mobile loops in HMBS that have
challenged experimental methods. Secondly, these predicted
structures may well allow new crystallization constructs that
can be used to explore different crystal packings and further
crystallizations at the functional pH of the enzyme. Such
crystallization constructs would allow new avenues to be
explored to grow larger crystals for neutron crystallography, as
well as the application of macroseeding methods (Chayen et
al., 2010).
The community of researchers interested in this fascinating
enzyme is growing, as shown by the pace of entries in Table 1.
I hope that this topical review proves useful to further expand
this community.
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